News >

Wang Explores Feasibility of CAR T Cells, Personalized Medicine in MCL

Caroline Seymour
Published: Tuesday, Jul 16, 2019

Michael Wang, MD

Michael Wang, MD

Patients with high-risk mantle cell lymphoma (MCL) are likely to relapse during their treatment course despite the use of BTK inhibitors, chemotherapy, transplant, and radiation, explained Michael Wang, MD. This has prompted investigations into promising alternatives, such as CAR T-cell therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication